Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

The possibility to analyse the tumour genetic material shed in the blood is undoubtedly one
of the main achievements of translational research in the latest years. In the modern clinical …

Upfront tumour genotyping is now considered an essential step in guiding treatment
decision-making in the management of patients with advanced-stage non-small-cell lung …

Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …

Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …

The last decade has seen rapid progress in the use of genomic tests, including gene panels,
whole‐exome sequencing, and whole‐genome sequencing, in research and clinical cancer …

Purpose: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing
concordance for comprehensive oncogenic driver detection in non–small cell lung cancer …

Background The APPLE trial aimed to evaluate the feasibility of longitudinal plasma
epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing strategy …